Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Mark Cuban's pharmaceuticals startup ties up with RxPreferred

Published 01/11/2023, 12:00 PM
Updated 01/11/2023, 04:31 PM
© Reuters. FILE PHOTO: Entrepreneur Mark Cuban speaks on a panel during the SXSW (South by Southwest) conference and festivals in Austin, Texas, U.S. March 14, 2022.  REUTERS/Montinique Monroe

(Reuters) - Billionaire entrepreneur Mark Cuban's pharmaceuticals startup has tied up with pharmacy benefits manager RxPreferred Benefits, the companies said on Wednesday, in a move to offer lower priced drugs through some employer-backed health insurance plans.

Mark Cuban Cost Plus Drugs provides generic drugs through direct contracts with manufacturers and charges a standard markup on every drug it sells.

Under the partnership, RxPreferred Benefits' customers will have the option to use Mark Cuban Cost Plus Drugs as part of their health insurance plans.

"Our partnership with RxPreferred is another step in the direction of bringing transparency to healthcare and lowering drug costs for individuals and families across the country" Cuban said in a statement.

Mark Cuban Cost Plus Drugs in December partnered with EmsanaRx, a nonprofit coalition of nearly 40 companies including U.S. retailers Walmart (NYSE:WMT) and Costco (NASDAQ:COST), that operates a PBM service for employers.

PBMs serve as intermediaries between drug manufacturers, health insurance plans and pharmacies to negotiate prescription drug prices.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.